References
- Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124:901–905.
- Titova N, Padmakumar C, Lewis SJG, et al. Parkinson’s: a syndrome rather than a disease? J Neural Transm. 2017;124:907–914.
- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601.
- Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72:S1–136.
- Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord. 2004;19:997–1005.
- Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol. 2010;63:257–266.
- Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458.
- Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20:224–230.
- Hechtner MC, Vogt T, Zollner Y, et al. Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord. 2014;20(9):969-974.
- Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2006. Neurology.
- Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129–2170.
- Saha RA, Worth PF, Stamford J. Assessing quality of life in Parkinson’s in routine clinical settings. ACNR. 2015;14:12–14.
- Stone AA, Shiffman S, Schwartz JE, et al. Patient non-compliance with paper diaries. BMJ. 2002;324:1193–1194.
- Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson’s disease clinical trials. CNS Neurosci Ther. 2012;18:380–387.
- Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson’s disease: challenges and opportunities. Mov Disord. 2016;31:1272–1282.
- Press release: CE mark awarded to second generation PKG™ system. [cited 2018 May 1]. Available from: https://www.globalkineticscorporation.com.au/news-and-events/ce-mark-awarded-to-second-generation-pkg-system?page=4
- Press release: FDA clearance received for second generation Parkinson’s KinetiGraph™. [cited 2018 May 1]. Available from: https://www.globalkineticscorporation.com.au/news-and-events/fda-clearance-received-for-second-generation-parkinsons-kinetigraph?page=4
- Griffiths RI, Kotschet K, Arfon S, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson’s disease. J Parkinsons Dis. 2012;2:47–55.
- Yanagisawa N, Fujimoto S, Tamaru F. Bradykinesia in Parkinson’s disease: disorders of onset and execution of fast movement. Eur Neurol. 1989;29(Suppl 1):19–28.
- van Hilten JJ, van Eerd AA, Wagemans EA, et al. Bradykinesia and hypokinesia in Parkinson’s disease: what’s in a name? J Neural Transm. 1998;105:229–237.
- O’Boyle DJ, Freeman JS, Cody FW. The accuracy and precision of timing of self-paced, repetitive movements in subjects with Parkinson’s disease. Brain. 1996;119(Pt 1):51–70.
- Horne MK, McGregor S, Bergquist F. An objective fluctuation score for Parkinson’s disease. PLoS One. 2015;10:e0124522.
- Braybrook M, O’Connor S, Churchward P, et al. An ambulatory tremor score for Parkinson’s disease. J Parkinsons Dis. 2016;6:723–731.
- Kotschet K, Johnson W, McGregor S, et al. Daytime sleep in Parkinson’s disease measured by episodes of immobility. Parkinsonism Relat Disord. 2014;20:578–583.
- Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30:80–89.
- Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726–733.
- Melamed E, Bitton V, Zelig O. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clin Neuropharmacol. 1986;9:182–188.
- Isaacson S, Lew M, Ondo W, et al. Apomorphine subcutaneous injection for the management of morning Akinesia in Parkinson’s disease. Mov Disord Clin Pract. 2017;4:78–83.
- Stacy M, Murck H, Meng X. COMPASS-1: a validation study of the 9-question, wearing off questionnaire (WOQ-9). Mov Disord. 2006;21:S590.
- Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(12):2169-2175.
- Matthews H, Stamford J, Saha R, et al. Off-park survey steering g. Exploring issues around wearing-off and quality of life: the OFF-PARK survey of people with Parkinson’s disease and their care partners. J Parkinsons Dis. 2015;5:533–539.
- AAPC: What to do when your patient is a “Poor Historian”. 2014 [cited 2017 Nov]. Available from: https://www.aapc.com/blog/27881-what-to-do-when-your-patient-is-a-poor-historian/
- Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–1496.
- Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82:1112–1118.
- Farzanehfar P, Braybrook M, Kotschet K, et al. Objective measurement in clinical care of patients with Parkinson’s disease: an RCT using the PKG [abstract]. Mov Disord. 2017;32(suppl 2). [cited 2018 May 1]. Available from: http://www.mdsabstracts.org/abstract/objective-measurement-in-clinical-care-of-patients-with-parkinsons-disease-an-rct-using-the-pkg/
- Garcia-Ruiz PJ, Del Val J, Fernandez IM, et al. What factors influence motor complications in Parkinson disease?: a 10-year prospective study. Clin Neuropharmacol. 2012;35:1–5.
- Kumar N, Van Gerpen JA, Bower JH, et al. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov Disord. 2005;20:342–344.
- Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83:384–388.
- Pietracupa S, Latorre A, Berardelli A, et al. Parkinsonian patients and poor awareness of dyskinesias. Front Neurol. 2014;5:32.
- Vitale C, Pellecchia MT, Grossi D, et al. Unawareness of dyskinesias in Parkinson’s and Huntington’s diseases. Neurol Sci. 2001;22:105–106.
- Sitek EJ, Soltan W, Wieczorek D, et al. Assessing self-awareness of dyskinesias in Parkinson’s disease through movie materials. Funct Neurol. 2011;26:121–126.
- Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 2001;57: S34–S38. 1992.
- Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad Hoc scientific committee. Mov Disord. 1998;13(Suppl 3):2–23.
- Nonnekes J, Timmer MH, de Vries NM, et al. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord. 2016;31:1602–1609.
- Price J, Martin H, Ebenezer L, et al. Evaluation of the clinical use of Parkinson’s KinetiGraph (PKG) movement recording system in the assessment of Parkinson’s disease patients with tremor [abstract]. Mov Disord. 2017;32(suppl 2). [cited 2018 May 1]. Available from: http://www.mdsabstracts.org/abstract/a-service-evaluation-of-the-clinical-use-of-parkinsons-kinetigraph-pkg-movement-recording-system-in-the-assessment-of-parkinsons-disease-patients-with-tremor/
- Arnulf I. Excessive daytime sleepiness in Parkinsonism. Sleep Med Rev. 2005;9:185–200.
- Arnulf I, Leu-Semenescu S. Sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S101–S104.
- Jitkritsadakul O, Bhidayasiri R. Physicians’ role in the determination of fitness to drive in patients with Parkinson’s disease: systematic review of the assessment tools and a call for national guidelines. J Clin Mov Disord. 2016;3:14.
- Merino-Andreu M, Arnulf I, Konofal E, et al. Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness. Neurology. 2003;60:1553–1554.
- Horne M, Volkmann J, Sanneli C, et al. An evaluation of the Parkinson’s Kinetigraph (PKG) as a tool to support deep brain stimulation eligibility assessment in patients with Parkinson’s disease [abstract]. Mov Disord. 2017;32(suppl 2). [cited 2018 May 1]. Available from: http://www.mdsabstracts.org/abstract/an-evaluation-of-the-parkinsons-kinetigraph-pkg-as-a-tool-to-support-deep-brain-stimulation-eligibility-assessment-in-patients-with-parkinsons-disease/
- Koivu M, Scheperjans F, Pekkonen E. Ambulatory movement measurement in evaluating deep brain stimulation effect in patients with advanced Parkinson’s disease [abstract]. Mov Disord. 2017;32(suppl 2). [cited 2018 May 1]. Available from: http://www.mdsabstracts.org/abstract/ambulatory-movement-measurement-in-evaluating-deep-brain-stimulation-effect-in-patients-with-advanced-parkinsons-disease/
- Willows T, Dizdar N, Nyholm D, et al. Initiation of levodopa-carbidopa intestinal gel infusion using telemedicine (Video communication system) facilitates efficient and well-accepted home titration in patients with advanced Parkinson’s disease. J Parkinsons Dis. 2017;7:719–728.
- Willis AW, Schootman M, Evanoff BA, et al. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology. 2011;77:851–857.
- Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: the example of Parkinson’s disease. Lancet Neurol. 2017;16:541–551.
- Beck CA, Beran DB, Biglan KM, et al. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017;89:1152–1161.
- Pasluosta CF, Gassner H, Winkler J, et al. An emerging era in the management of Parkinson’s disease: wearable technologies and the internet of things. IEEE J Biomed Health Inform. 2015;19:1873–1881.
- Farzanehfar P, Woodrow H, Braybrook M, et al. Objective measurement in routine care of people with Parkinson’s disease improves outcomes. NPJ Parkinsons Dis. 2018;4:10.
- Odin P, Chaudhuri KR, Volkmann J, et al. Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease. Npj Parkinson’s Dis. 2018;4. Article number: 14. DOI:10.1038/s41531-018-0051-7
- Farzanehfar P, Horne M. Evaluation of the Parkinson’s KinetiGraph in monitoring and managing Parkinson’s disease. Expert Rev Med Devices. 2017;14:583–591.
- Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20:1502–1507.
- Horne M, Kotschet K, McGregor S. The clinical validation of objective measurement of movement in Parkinson’s disease. CNS. 2016;2:16–23.
- Evans AH, Kettlewell J, McGregor S, et al. A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson’s disease. PLoS One. 2014;9:e89319.
- Ossig C, Gandor F, Fauser M, et al. Correlation of quantitative motor state assessment using a Kinetograph and patient diaries in advanced PD: data from an observational study. PLoS One. 2016;11:e0161559.
- Titova N, Martinez-Martin P, Katunina E, et al. Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed. J Neural Transm. 2017;124:1529–1537.